CHMP recommends EU approval of Roche’s Gazyvaro for people with previously treated follicular lymphoma

Roche announced today that the EU Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Gazyvaro® (obinutuzumab) in combination with bendamustine chemotherapy followed by Gazyvaro maintenance as a new treatment for people with follicular lymphoma who did not respond to, or who progressed during or up to six months after treatment with MabThera® (rituximab) or a MabThera-containing regimen.
Source: Roche Media News - Category: Pharmaceuticals Source Type: news

Related Links:

Publication date: Available online 23 March 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Hiroshi Ureshino, Kazuharu Kamachi, Shinya KimuraAbstractMogamulizumab, a defucosylated humanized monoclonal antibody against C–C chemokine receptor 4 (CCR4), has been approved for the treatment of relapsed adult T-cell leukemia/lymphoma (ATL). Compared with conventional chemotherapy, mogamulizumab monotherapy displayed more effecacy in relapsed ATL making mogamulizumab a promising therapeutic agent. However, mogamulizumab could increase graft-versus-host disease, resulting in poor survival outcome in allogenic st...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
CONCLUSIONS:: This report describes an extremely rare case of a tracheal IMT, underlying the key role of radiotherapy as adjuvant treatment able to definitively cure IMT, limiting systemic chemotherapy-related toxicity. PMID: 30900517 [PubMed - as supplied by publisher]
Source: Tumori - Category: Cancer & Oncology Tags: Tumori Source Type: research
Publication date: 1 May 2019Source: Chemico-Biological Interactions, Volume 304Author(s): M.F. Nagoor Meeran, Hasan Al Taee, Sheikh Azimullah, Saeed Tariq, Ernest Adeghate, Shreesh OjhaAbstractThe cannabinoid type 2 receptor (CB2) has recently emerged as an important therapeutic target for cancer as well as cardiovascular diseases. The CB2 receptor downregulation has been reported in solid tumors and cardiovascular diseases, therefore the CB2 receptor activation has been considered as a viable strategy for chemotherapy as well as cardioprotection. Doxorubicin (DOX) is an important drug that continues to be the mainstay of ...
Source: Chemico Biological Interactions - Category: Biochemistry Source Type: research
Authors: Shen H, Ji Y, Zhou D, Zhang Y, Wang W, Sun J, Zhang W Abstract PURPOSE: To investigate the role of soluble programmed cell death ligand 1 (sPD-L1) protein in plasma of patients with Peripheral T-cell lymphoma (PTCL). METHODS: In total, 80 patients with newly diagnosed PTCL and 75 healthy controls were enrolled. Levels of sPD-L1 were measured by ELISA at diagnosis and after 3-8 courses of chemotherapy. The expression of PD-L1 in tumor tissues from nine PTCL patients was also detected. RESULTS: sPD-L1 was higher in PTCL patients at diagnosis compared to healthy subjects (P 
Source: Hematology - Category: Hematology Tags: Hematology Source Type: research
Syncytial variant of nodular sclerosis (SV-NS) classical Hodgkin lymphoma (cHL) with its histologic features and clinical presentation is uncommon in adults and extremely rare in children. Here, we report a female teenager presenting with long-standing B symptoms, prominent soft tissue and bone involvement mimicking sarcoma and significant nodal disease who is diagnosed with advanced SV-NS cHL. Rare Reed-Sternberg-like cells displaying neutrophil and erythrocyte emperipolesis were seen on bone marrow aspiration slides. Despite initial complete response to chemotherapy and radiotherapy, the patient experienced early relapse...
Source: Journal of Pediatric Hematology Oncology - Category: Hematology Tags: Online Articles: Clinical and Laboratory Observations Source Type: research
This report describes the case of a 10-year-old boy who presented with an intracardiac mass and tumor thrombosis in the anterior mediastinum that proved to be Burkitt lymphoma. The LMB-96 chemotherapy protocol was given and at the end of the treatment there was still residual mass. A biopsy was performed and the pathology revealed thymus tissue. The patient has been in complete remission for 3 months. Burkitt lymphoma has a short doubling time and an intracardiac lesion can become life threatening. Early recognition and prompt treatment are crucial in achieving optimal outcomes.
Source: Journal of Pediatric Hematology Oncology - Category: Hematology Tags: Online Articles: Clinical and Laboratory Observations Source Type: research
Mogamulizumab, a defucosylated humanized monoclonal antibody against C –C chemokine receptor 4 (CCR4), has been approved for the treatment of relapsed adult T-cell leukemia/lymphoma (ATL). Compared with conventional chemotherapy, mogamulizumab monotherapy displayed more effecacy in relapsed ATL making mogamulizumab a promising therapeutic agent. However, mogamulizuma b could increase graft-versus-host disease, resulting in poor survival outcome in allogenic stem cell transplant (allo-SCT) setting.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Review Article Source Type: research
Conditions:   Solid Tumor;   Lymphoma Interventions:   Drug: TTX-030;   Drug: Pembrolizumab;   Drug: Docetaxol;   Drug: Gemcitabine;   Drug: nab paclitaxel Sponsor:   Tizona Therapeutics, Inc Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Authors: Fallah J, Olszewski AJ Abstract OBJECTIVES: To examine the use of splenectomy, chemotherapy, and subsequent overall survival (OS) in contemporary patients with splenic lymphomas. METHODS: We analyzed records of 6450 patients with various splenic lymphomas recorded in the National Cancer Data Base (2004-2013). Survival was compared using Mantel-Byer test to account for guarantee-time bias, stratified by age, sex, comorbidities, and lymphoma stage. RESULTS: Splenectomy rate was overall 58%, and varied from 49% in splenic marginal zone (SMZL) to 77% in follicular lymphoma (FL). It significantly decrea...
Source: Hematology - Category: Hematology Tags: Hematology Source Type: research
Although generally curable with intensive chemotherapy in resource-rich settings, Burkitt lymphoma (BL) remains a deadly disease in older patients and in sub-Saharan Africa. Epstein-Barr virus (EBV) positivity is a feature in more than 90% of cases in malaria-endemic regions, and up to 30% elsewhere. However, the molecular features of BL have not been comprehensively evaluated when taking into account tumor EBV status or geographic origin. Through an integrative analysis of whole-genome and transcriptome data, we show a striking genome-wide increase in aberrant somatic hypermutation in EBV-positive tumors, supporting a lin...
Source: Blood - Category: Hematology Authors: Tags: Pediatric Hematology, Lymphoid Neoplasia Source Type: research
More News: Chemotherapy | Lymphoma | Pharmaceuticals | Rituxan | Treanda